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Sweden and Norway: a drug utilization
study from 2014 to 2017
Christer F. Aas1,2,3* , Jørn Henrik Vold1,2, Svetlana Skurtveit4, Ingvild Odsbu5, Fatemeh Chalabianloo1,2,
Aaron G. Lim6, Kjell Arne Johansson1,2 and Lars Thore Fadnes1,2
Abstract
Background: Treatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C
virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT)
programs. The objective of this study was to estimate and to compare HCV treatment uptake after the introduction
of DAAs among patients receiving OAT in Sweden and Norway. We also aimed to evaluate predictors of DAAs
treatment among OAT patients in both countries.
Methods: This observational study was conducted with data from The Swedish Prescribed Drug Register and The
Norwegian Prescription Database. We studied dispensed medications to calculate HCV treatment among OAT
patients from 2014 to 2017 in Sweden and Norway. HCV prevalence was estimated from primary and secondary
sources. Dispensations of medicines from different therapeutic areas, which served as proxy for co-morbidities in
2017, were conditionally adjusted for age, gender, and OAT medications. Logistic regression was used to evaluate
these parameters.
Results: In total 3529 individuals were identified with dispensed OAT in the Swedish cohort and 7739 individuals in
the Norwegian cohort. HCV treatment was utilized by 407 persons in Sweden and 920 in Norway during the study
period. Annual HCV and DAA treatment uptake increased in both countries. The estimated cumulative HCV
treatment uptake at the end of 2017 was 31% in Norway and 28% in Sweden. DAA treatment was associated with
increased age (aOR 1.8; 95% CI 1.0–3.2) and the dispensation of drugs used for diabetes (aOR 3.2; 95% CI 1.8–5.7) in
Sweden. In Norway, lipid modifying agents and antibacterials were associated with decreased odds (aOR 0.4; 95%CI
0.2–0.9, aOR 0.8; 95%CI 0.6–1.0).
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Conclusions: An increase in DAA treatment and HCV treatment uptake was observed among Swedish and
Norwegian OAT patients whilst introducing new direct-acting antiviral treatment regimens. However, more than
two thirds of the OAT population in Norway and Sweden were untreated at the beginning of 2018. A further scale-
up is crucial in order to control and eliminate the HCV endemic among OAT patients.
Keywords: Hepatitis C, Chronic hepatitis C, Treatment uptake, Direct-acting antivirals, Opioid substitution treatment
Background
Treatment of chronic hepatitis C virus (HCV) infection
has been subject to vivid changes in the last few years
with the introduction of direct-acting antiviral agents
(DAAs) [1]. The ambition of any antiviral treatment of
HCV infection is elimination of the virus. In that sense,
standard treatment prior to 2011 was a combination of
pegylated interferon alpha and ribavirin, which saw a
sustained virologic response (SVR) in approximately 50
to 56% of patients [1, 2]. SVR is defined as absence of
HCV RNA 12 weeks after end of treatment. However,
since 2011 various DAAs have become readily available
and should make interferon-based therapies almost ob-
solete. HCV policies including DAA offer countries an
opportunity to eliminate HCV endemics, with less side
effects, shorter treatment periods and improved adher-
ence as compared to old interferon treatment. Combin-
ing two (or three) DAAs have led to a SVR of far
beyond 90% also among patients who have been hard to
treat in the past [3, 4].
The scale of the HCV endemic among people who in-
ject drugs (PWID) is tragic and is a result of years of
failing health policies for vulnerable populations. The
HCV prevalence is around 50%, or more, among PWIDs
[5, 6], and around 50% among patients on opioid agonist
therapy (OAT) [7]. It is estimated that HCV complica-
tions will continue to increase within the next few years
[8]. DAA treatment has been offered as universal health
coverage from 2017 and 2018 in Sweden and Norway,
respectively [9, 10]. It seems, however, that the increased
accessibility has not benefitted active-PWIDs [11].
The coverage of preventive interventions and harm re-
duction services varies among PWIDs. Although the dis-
tribution of needle and syringe programs is relatively poor
[12], opioid treatment programs such as OAT has higher
coverage in many countries [13]. OAT has shown to re-
duce the risk of HCV acquisition [14], and despite on-
going illicit drug use, patients on OAT are achieving high
SVR rates [15]. Hence, OAT programs may be a critical
intervention for achieving large reductions in HCV trans-
missions. Several studies have shown that significant re-
ductions in HCV prevalence can be achieved with an
adequate increase in HCV treatment uptake [16–18].
Nevertheless, HCV treatment uptake has remained low
[19, 20]. In Norway, annual HCV treatment uptake among
OAT patients ranged from 1.3 to 2.6% in the period from
2004 to 2013 [20]. HCV treatment uptake, and in particu-
lar DAA treatment, among OAT patients in Sweden is un-
known. Norway and Sweden share a basic cultural unity,
have a comparable socioeconomic and political structure
with similar health care systems that are based on the
Nordic welfare model [21]. Taking into consideration the
potential for HCV disease elimination by publicly funded
DAA policies in these countries [9, 13] and the high HCV
prevalence among the OAT population, it is essential to
calculate the DAA treatment within an OAT delivery plat-
form. Such estimates are important for countries aiming
for HCV elimination or endemic control in the near
future.
Therefore, this observational study aims to:
1) calculate HCV treatment annually and cumulatively
after the introduction of DAAs among patients
receiving OAT in Sweden from 2014 to 2017
2) compare DAA treatment between Sweden and
Norway among patients receiving OAT from 2014
to 2017 and estimate the HCV treatment uptake
3) evaluate if various dispensed drugs (proxy for
comorbidities), age, gender and OAT medication is
associated with DAA treatment among OAT
patients in Sweden and Norway in 2017
Methods
Study design and data sources
This is an observational study among patients on OAT
in Sweden and Norway from 2014 to 2017. Data were
extracted from The Swedish Prescribed Drug Register
and The Norwegian Prescription Database. The regis-
tries cover the entire Norwegian and Swedish popula-
tions and record all drugs dispensed from pharmacies.
All drugs are classified according to The Anatomical
Therapeutic Chemical (ATC) classification system [22].
HCV prevalence data is not readily available for Norway
and Sweden. Consequently, we employed primary and
secondary sources to model HCV prevalence. Data from
the INTRO-HCV study in Norway [23] was used in
addition to published data on HCV prevalence among a
large cohort of Swedish PWIDs [24]. See additional file 1
for a comprehensive description of methodology and
data sources.
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Study population and definitions
The study population included all individuals aged 18 to
75 years who received OAT in Sweden and Norway.
OAT was defined as being dispensed at least one defined
daily dose (DDD) per day per calendar year of buprenor-
phine, methadone, buprenorphine-naloxone, or levo-
methadone by summarizing all annually dispensed OAT
DDDs divided by 365.25 days.
Moreover, OAT medication per individual was noted
as the last dispensation per calendar year. To avoid in-
cluding other medical indications than OAT, we ex-
cluded methadone preparations on the basis of route of
administration (injections and tablets), and introduced a
dosage criteria in order to make sure that actual patients
on OAT were captured. The dosage criteria was set at
minimum one DDD daily throughout each calendar year
as an inclusion criteria. The study populations were thus
chosen annually for both countries and it was possible
for an individual to be included in more than one calen-
dar year. See additional file 2 for a flow chart. ATC/
DDDs according to 2017 [25] were used to quantify the
dispensed OAT medications. A more detailed descrip-
tion of OAT and HCV treatment in Sweden and Norway
is provided in additional file 3.
Calculating HCV and DAA treatment and estimating
treatment uptake
HCV treatment was defined as being dispensed either
one or more types of pegylated interferon alpha in com-
bination with ribavirin, or one or more of the DAAs per
calendar year during the study period (additional file 4).
For each country, the annual HCV treatment rates were
calculated by dividing the number of individuals with
dispensed HCV treatment by the number of individuals
on OAT. The cumulative HCV treatment frequency,
which is the sum of successive years of treatment, was
then calculated as the proportion of patients with dis-
pensed HCV treatment at some point during the study
period. Similarly, DAA treatment was calculated by div-
iding the number of OAT patients with at least one dis-
pensation of DAA by the total number of OAT patients
per year, which represents the annual prevalence of
DAA use among OAT patients. Using primary and sec-
ondary sources, along with several assumptions, as
described in detail in additional file 1, we derived a for-
mula to estimate the chronic HCV prevalence in Sweden
and Norway as follows;
Expected Number of Chronic HCV
¼ 1−δð Þ ϕπPWIDþ 1−ϕð ÞπNonPWID½ Nð Þ−τ
where N is the size of the study population, δ is the rate
of spontaneous HCV clearance, ϕ is the proportion of
OAT patients who are PWID, πPWID and πNonPWID are
the anti-HCV prevalence estimates among PWID and
non-PWID, respectively, and τ is the number of HCV
treatments given. Using the above formula, we calculate
the expected number of chronic HCV infections in
2014–2017 for Norway and Sweden, with uncertainty in
this quantity arising only from the uncertainty in spon-
taneous clearance. The chronic HCV prevalence was
then calculated by dividing the expected number of
chronic HCV infections by the total population size in
that particular year and setting (i.e. Norway or Sweden).
HCV treatment uptake was then estimated by dividing
the HCV treatments in each year by the estimated num-
ber of chronic HCV infections in that same year, yield-
ing a percentage of chronic HCV infections that were
treated per year. The cumulative HCV treatment uptake
was then calculated as the sum of HCV treatment up-
take across years.
Potential predictors associated with DAA treatment up-
take were determined a priori and included OAT medica-
tion (methadone/levomethadone vs. buprenorphine-based),
age, gender and various dispensed drugs (yes vs. no) from
different therapeutic areas that were used as proxies for co-
morbidities. All dispensations were recorded at the second
ATC level (therapeutic subgroup), except for drugs affect-
ing the nervous system.
Statistical analyses
All data analyses was conducted in STATA SE 16.0 (Sta-
taCorp, TX, USA). Descriptive data was presented as fre-
quencies, percentages, and means, with corresponding
95% confidence intervals where appropriate. Logistic re-
gression was used to estimate whether DAA treatment
uptake was associated with gender, age, OAT medica-
tion, and dispensations of other drugs in 2017. Statistical
significance was set at the p < 0.05 level.
Data handling and ethical considerations
All data were received pseudonymised from registry ad-
ministrators and subsequently analyzed, therefore, no
written consent was obtained from any of the individuals
in the study. The study was approved by the Regional Eth-
ical Review Committee in Stockholm, Sweden, (no 2018/
2080–31/1) and the Regional Committee for Ethics in
Medical Research (no. 2018/939) in Norway. Furthermore,
the study was conducted in accordance with the Helsinki
Declaration and as an observational study in accordance
with international accepted STROBE guidelines [26].
Results
Basic characteristics
In Sweden, 3529 individuals receiving OAT were identi-
fied. Around 70% were male, with a mean age of ap-
proximately 44 years and 45 years in 2014 and 2017,
respectively. See additional file 5. The majority of the
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OAT patients were treated with buprenorphine-based
OAT medication (52% in 2014 and 56% in 2017).
Altogether 407 individuals in the Swedish cohort re-
ceived HCV treatment during the study period. In
Norway, 7739 individuals were identified during the
study period from 2014 to 2017. 70% were male and
mean age was 44 in 2014 and almost 46 years in 2017.
55% received treatment with a buprenorphine-based
OAT medication in 2017. Altogether 920 individuals in
the Norwegian cohort received HCV treatment during
the study period (Table 1).
Estimated HCV prevalence and treatment uptake
For Sweden, chronic HCV prevalence was estimated to
range from 55.6% (uncertainty interval (UI) 53.3 to 58.8)
in 2014, to 53.1 (UI: 50.8–56.3) in 2017. In Norway,
prevalence was estimated from 54.4 (UI: 52.1–57.5) in
2014 to 50.0 (UI: 47.7–53.1) in 2017. The cumulative
HCV treatment uptake was thus projected to be 31% in
Norway and 28% in Sweden for the study period
(Table 2). Unadjusted treatment rates for both countries
are shown in additional file 6, (Fig. 1).
Dispensations and predictors of DAA treatment in 2017
OAT patients in Norway and Sweden were stratified ac-
cording to whether they received DAA treatment or not,
and compared in 2017. In the Norwegian cohort 366 in-
dividuals (6.6%) received DAA treatment whereas in
Sweden, 123 (4.5%) individuals received treatment. Vari-
ations in treatment within countries were few, except for
drugs used for diabetes (Table 3). However, among indi-
viduals receiving DAA treatment in Norway, half were
also dispensed benzodiazepines compared to only 15%
in Sweden. In contrast, 24 and 31% of the Swedish pa-
tients treated with DAA also received dispensations of z-
hypnotics and antidepressants compared to 15 and 20%
in the Norwegian cohort, respectively.
In a logistic regression model (additional file 7), DAA
treatment was associated with increased age (adjusted
odds ratio (aOR) 1.8; 95% CI 1.0–3.2) and dispensation
of drugs used in diabetes (aOR 3.2; 95% CI 1.8–5.7) in
Sweden. Dispensations of lipid modifying agents and an-
tibacterials were associated with decreased odds (aOR
0.4; 95% CI 0.2–0.9, aOR 0.8; 95% CI 0.6–1.0) of receiv-
ing DAA treatment in Norway. Moreover, being female
was associated with decreased odds in both countries (S:
aOR 0.6; 95% CI 0.3–0.9, N: aOR 0.8; 95% CI 0.6–1.0).
Discussion
Amid the hepatitis C endemic among PWIDs and indi-
viduals enrolled in OAT programs in Sweden and
Norway, the study has revealed a large increase in DAA
treatment uptake among OAT patients in both countries
from 2014 to 2017. As such, our findings reflect the im-
mense progress, which has been achieved in HCV treat-
ment during the recent years with almost a complete
shift from interferon-based treatment to solely treatment
with DAAs among OAT patients. The cumulative fre-
quency of HCV treatment in the OAT population be-
tween 2014 and 2017 was estimated to be 28 and 31%%
in Sweden and Norway, respectively.
Despite substantial increase in HCV treatment uptake in
advanced health systems like Sweden and Norway, as found
in our study, the treatment uptake is still too low and pro-
gress too slow globally [20, 28, 29]. Treatment demand has
soared after the introduction of DAAs, especially among
former PWIDs [11], while people who are still using drugs
actively have seemingly not been fully able to benefit from
the increased accessibility [11]. In order to reach universal
health coverage of DAAs and elimination of HCV, more ef-
forts are needed in countries. Coverage of DAAs varied sub-
stantially across European countries, ranging from 0.6 to
10.2% in 2015 [30]. Restrictions in DAA access policies may
explain these variations. Among European countries,
England, Hungary, Croatia and Slovakia experienced one of
the most restricted access policies to DAA treatment com-
pared to Poland, Ireland, the Netherlands, France and
Germany, which had the least restrictions during the study
period [31]. Our findings saw Sweden with a greater DAA
treatment uptake than Norway in 2015, and roughly in the
Table 1 Basic characteristics of patients receiving OAT in 2014
and 2017 in Sweden and Norway
2014 2017
Country Sweden Norway Sweden Norway
OAT studypopulation, n 2663 6057 2739 5545
Gender, n (%)
Male 1911 (72) 4266 (70) 1961 (72) 3870 (70)
Female 752 (28) 1791 (30) 778 (28) 1675 (30)
Age, n (%)
18–35 671 (25) 1219 (20) 647 (24) 878 (16)
36–45 817 (31) 2181 (36) 819 (30) 1747 (32)
46–55 744 (28) 2044 (34) 713 (26) 1998 (36)
56–75 431 (16) 613 (10) 560 (20) 922 (17)
Mean age (SD)
Male 44 (10) 44.1 (9) 45.1 (11) 46.1 (9)
Female 43.5 (11) 43.1 (9) 44.3 (12) 45.2 (10)
OAT medication, n (%)a
Methadone/
levomethadone
1267 (48) 2810 (46) 1198 (44) 2504 (45)
Buprenorphine 875 (33) 2049 (34) 1075 (39) 2190 (40)
Buprenorphine/naloxone 521 (20) 1198 (20) 466 (17) 851 (15)
Sources: The Swedish Prescribed Drug Register (SPDR), The Norwegian
Prescription Database (NorPD)
OAT Opioid agonist therapy, SD Standard deviation
aLast registered OAT medication each calendar year
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middle among its European counterparts, similar to the last
Scandinavian country, Denmark, at close to 4% [30]. An-
other reason for the low treatment uptake might be con-
cerns about treatment compliance among PWIDs and OAT
patients; however, this seems unwarranted as both good ad-
herence and high SVR rates in this group have been docu-
mented in several randomized controlled trials [32, 33].
Arguably, poor treatment uptake of DAAs globally and
a hard to reach population opts for countries to consider
alternative health service delivery platforms. Addressing
barriers to HCV treatment and testing are important.
Between 60 and 70% of people enrolled in various opioid
treatment programs are offered onsite testing for HCV
[29], which is too low. OAT programs could thus benefit
from introducing universal HCV testing and linkage to
care in OAT settings. Perhaps OAT programs, together
with infectious disease and gastroenterology/hepatology
specialists, could explore any opportunities for non-spe-
cialists to dispense DAA regimens to increase treatment
uptake. Psychoeducation to improve knowledge among
OAT patients regarding treatment, possible side effects
and HCV infection seems to improve both SVR rates and
adherence to treatment and should also be considered im-
plemented in an OAT setting [34]. Furthermore, current
drug use or any fear of reinfection in patients already
treated for HCV should not hinder treatment with DAA.
Reinfections seems to be low (1–5%), even if treated pa-
tients return to active drug use [35].
The differences between Sweden and Norway are in-
teresting and relevant for other settings. Prevalence of
anti-HCV among PWIDs seems consistently higher in
Sweden compared to Norway [36, 37]. Coverage of OAT
is higher in Norway than Sweden. Waal et al. estimate
an overall OAT coverage of around 60% among people
Fig. 1 Estimated HCV treatment uptake in Norway and Sweden among OAT patients from 2014 to 2017. HCV = hepatitis C virus infection, OAT =
opioid agonist therapy. Sources OAT and HCV treatment: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database
(NorPD). Prevalence: Intro-HCV = Integrated treatment of hepatitis C study, Kåberg et al. [24]: Prevalence of hepatitis C and pre-testing awareness
of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program, Micallef et al. [27]: Spontaneous viral
clearance following acute hepatitis C infection: a systematic review of longitudinal studies. For more comprehensive details on sources and
model calculation, see additional file 1.
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with opioid dependence in Norway [38] compared to 10
to 50% OAT coverage in Sweden [39]. Differences in
OAT eligibility criteria could explain lower coverage of
OAT in Sweden as compared to Norway. Norway
altered its OAT guidelines in 2010, making opioid addic-
tion the absolute criteria for inclusion and being retained
in treatment, and there is a high threshold for dischar-
ging patients from OAT. However in Sweden, current
OAT guideline has lower thresholds for OAT cessation
in the case of repeated illicit drug use [7, 40]. The two
populations may therefore be different and Swedish
OAT patients could have less ongoing drug use, which
could lower the risk of HCV and increase the chance for
HCV treatment success. However, the Norwegian strat-
egy could be more effective at a population level since
hard to reach groups are included and illicit drug use is
not considered as an exclusion criterion for OAT.
With the provision of DAA treatment available for all
Swedish and Norwegian patients, it may be tempting to
argue that this is the beginning of the end for the HCV
endemic. In addition to OAT, maintaining a high cover-
age of needle and syringe availability in these countries,
together with continued scale-up of DAA treatment, it
may be possible to reduce incidence by 90% by 2030 as
shown in a modeling study from the UK [41]. On the
other hand it may still seem embryonic as there may be
shortcomings in current HCV surveillance systems.
HCV has been notified to The Norwegian Surveillance
System for Communicable Diseases since 1990, yet,
there has been no distinction between anti-HCV, HCV
RNA or HCV core antigen reporting before 2016 [20].
Hence, accurate HCV prevalence and incidence data
prior to 2016 are not readily available. Furthermore, in
order to eliminate HCV as a public health threat by
2030, which both countries have embraced, a coherent
and structured national plan is essential. The Norwegian
Health Ministry introduced a national hepatitis C strat-
egy in 2016, and was later revised in 2018, which focuses
on DAA treatment, HCV surveillance, and prevention,
and aims to reduce HCV incidence by 90% within 2023
[42]. On the contrary, an ambitious national Swedish
hepatitis C plan has not yet been established [43].
Our findings suggest few inter-country differences in dis-
pensed drugs among those treated with DAAs and those
not, except for drugs used for diabetes in the Swedish co-
hort, which was significantly higher and demonstrated a
Table 3 Dispensed drugs to patients receiving OAT and OAT/DAAs in Norway and Sweden in 2017
Year 2017 2017
Country Norway Sweden
OAT study population, n 5543 2739
Only OAT DAA + OAT Only OAT DAA + OAT
5177 366 2616 123
Drugs No. (%) No. (%) No. (%) No. (%)
Drugs used in Diabetes 197 (4) 14 (4) 161 (6) 18 (15)
Antithrombotic agents 529 (10) 35 (10) 217 (8) 8 (7)
Cardiovascular system drugs a 842 (16) 67 (18) 622 (24) 37 (30)
Lipid modifying agents 271 (5) 10 (3) 121 (5) 4 (3)
Sex hormones and modulators of genital system 654 (13) 51 (14) 430 (16) 14 (11)
Antibacterials for systemic use 1901 (36) 112 (31) 915 (35) 33 (27)
Anti-inflammatory and ant-rheumatic products 1155 (22) 69 (19) 570 (22) 25 (20)
Drugs for obstructive airway diseases 1048 (20) 68 (19) 410 (16) 14 (11)
Benzodiazepinesb 2368 (46) 181 (50) 402 (15) 19 (15)
Hypnotics and sedativesc 797 (15) 54 (15) 691 (26) 30 (24)
Antiepilepticsd 823 (16) 57 (16) 629 (24) 25 (20)
Antidepressantse 960 (19) 73 (20) 1008 (39) 38 (31)
Antipsychoticsf 1401 (27) 85 (23) 602 (23) 28 (23)
Source: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD). All drugs on ATC Level 2, except under Nervous system. See
Supplement Table S2
OAT Opioid agonist therapy, DAA Direct-acting antiviral agents
aC01, C02, C03, C07, C08, C09
bN05BA01, N05BA04, N05BA06, N05BA12, N05CD02, N05CD03, N05CD08, N03AE01
cN05CF01 and N05CF02
dN03AA, N03AB, N03AF, N03AG, N03AX
eN06AA, N06AB, N06AF, N06AG, N06AX
fN05AA, N05AB, N05AC, N05AD, N05AE, N05AF, N05AG, N05AH, N05AL, N05AN, N05AX
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strong association with DAA treatment. Chronic HCV
might be a risk factor for developing immune system disor-
ders, heart disease and diabetes, especially diabetes type II
as the viral infection may increase insulin resistance [44,
45]. This finding was not mirrored in the Norwegian co-
hort. Dispensed drugs can serve as a proxy for co-
morbidity and it is well-established that both somatic and
especially mental illness are underdiagnosed and under-
treated among individuals with substance use disorders
[46]. This does not explain the vast differences we observed
among dispensations of benzodiazepines, z-hypnotics, and
antidepressants comparing Sweden and Norway. Older pa-
tients are more likely to have cirrhosis and longer HCV
treatment courses compared to younger patients. A reason
for the observed age difference may be that the younger pa-
tients are usually harder to reach due to an unstable life
situation and drug abuse related behavior. Similarly, the
analyses point toward women being less likely to be treated
for HCV, however, this could be due to women being un-
derrepresented in services.
Strengths and limitations
The national prescription registries capture large popu-
lations, and as such, provide researchers with precise
and near complete databases. The main strength of this
study is that it offers a large sample of OAT patients be-
ing treated for HCV.
However, this study has several limitations. As the pa-
tients were included each calendar year with a dosage
criteria, a patient who commenced treatment late or quit
early during the year may not obtain sufficient exposure
to be included in that particular year. Moreover, OAT
treatment in Norway and Sweden is not uniform. Most
individuals are dispensed OAT medications at pharma-
cies while others receive the drugs at OAT outpatient
clinics, which means that those latter patients are not
identified in this study. OAT and HCV treatment ad-
ministered to hospitalized and institutionalized patients
are also not recorded in the registries. In addition, DDD
does not necessarily reflect the prescribed daily dose.
Furthermore, HCV treatment uptake data was not linked
on an individual level to diagnosis codes of HCV according
to International Statistical Classification of Diseases and Re-
lated Health Problems version 10 (ICD-10) or the Inter-
national Classification of Primary Care (ICPC), rather, it
was estimated from published reports and modelled where
adequate data sources were missing. Thus, there is some
uncertainty in the denominator of people with HCV in
need of treatment. The predictors for DAA treatment were
limited to the main dispensed drugs and sociodemographic
variables and so did not fully acknowledge that there could
be other vital reasons why access to DAAs would be limited
in this group of patients.
Finally, PWID are a heterogeneous group of individ-
uals, and one should be careful not to generalize OAT
patients to include all PWIDs.
Conclusion
This study indicates a large scale-up in DAA treat-
ment among Swedish and Norwegian OAT patients.
Cumulative HCV treatment uptake was around one-
third from 2014 to 2017 in both countries, attributed
by a complete shift to DAA treatment regimens.
Amidst a HCV endemic among PWIDs, it seems that
two-thirds of OAT patients in need of treatment were
untreated in the beginning of 2018. Coupled with the
prospect of HCV elimination, there is a need for fur-
ther scale-up of the most effective HCV treatment
strategies, by identifying possible predictors of treat-
ment and to establish more accurate surveillance sys-
tems in order to provide better care to this group of
marginalized people.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13011-020-00286-2.
Additional file 1. Methodology description: estimating chronic hepatitis C
(HCV) prevalence among people on opioid agonist therapy (OAT) in Norway and
Sweden:
Additional file 2. Flowchart of study populations in Norway and Sweden
from 2014 to 2017. According to World Health Organization Collaborating
Centre for Drug Statistics Methodology, ATC/DDD Index. OAT = opioid
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